Study #2020-0123
Phase I Study of Reirradiation with NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC)
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This phase I trial investigates the best dose and side effects of NBTXR3 when given together with radiation therapy for the treatment of non-small cell lung cancer that cannot be treated by surgery (inoperable) and has come back (recurrent). NBTXR3 is a radio-enhancer designed to increase the radiotherapy energy dose deposition inside tumor cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving NBTXR3 and radiation therapy may increase radiation-dependent tumor cell killing without increasing the radiation exposure of healthy surrounding tissues.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Lung Non-Small Cell Carcinoma;Stage I Lung Cancer AJCC v8;Stage IA1 Lung Cancer AJCC v8;Stage IA2 Lung Cancer AJCC v8;Stage IA3 Lung Cancer AJCC v8;Stage IB Lung Cancer AJCC v8;Stage II Lung Cancer AJCC v8;Stage IIA Lung Cancer AJCC v8;Stage IIB Lung Cancer AJCC v8;Stage III Lung Cancer AJCC v8;Stage IIIA Lung Cancer AJCC v8;Stage IIIB Lung Cancer AJCC v8;Stage IIIC Lung Cancer AJCC v8;Unresectable Lung Non-Small Cell Carcinoma
Study phase:
Phase I
Physician name:
Saumil Gandhi
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.